ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, announced the completion of an oversubscribed $4.9M seed ...

In a set of newly released presentations, officials from the US Food and Drug Administration (FDA) explain changes to the agency's biomarker qualification program and detail early opportunities for ...

ViewsML, a company building the computational layer for biomarker discovery by transforming tissue analysis from a lab process into software, today announced the completion of an oversubscribed $4.9M ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic ...

Every decision in drug development carries weight. The right biomarker insights can make those decisions more confident and data-driven. In this white paper, experts from AstraZeneca, Johnson & ...

Drug development involves significant risk and expense. With average development costs topping $1 billion per approved medicine and stubbornly high failure rates, pharmaceutical leaders are ...

Key market opportunities in the CNS Biomarkers sector include utilizing AI and technologies like ML and NLP to enhance drug ...

Validated biomarkers will help physicians identify patient subgroups that will benefit most from specific treatment ...

Proteomics is emerging as a promising approach for identifying autism biomarkers by detecting protein-level changes linked to ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...